SAN DIEGO, California — August 20, 2025 — Leads & Copy — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) has announced the pricing of an underwritten public offering expected to generate $6 million in gross proceeds before deductions.
The offering includes 1,472,764 common stock units, each with one share of common stock and one Series I warrant, and 1,528,000 pre-funded warrant units, each with a pre-funded warrant and a Series I warrant. The price per Common Stock Unit is $2.00, and per Pre-Funded Unit is $1.999. Series I warrants are exercisable upon issuance at $2.00 per share, expiring five years from issuance.
Calidi has granted underwriters an option to purchase an additional 450,000 shares and/or warrants. The offering is set to close around August 21, 2025, pending standard conditions.
Ladenburg Thalmann & Co. Inc. is the sole book-running manager, with Laidlaw & Company (U.K.) Ltd. as co-manager.
Calidi Biotherapeutics, headquartered in San Diego, CA, is focused on targeted therapies for genetic medicine delivery to distal disease sites.
Dave Gentry, CEO of RedChip Companies, Inc., can be reached at 1-407-644-4256 or CLDI@redchip.com.
Source: Calidi Biotherapeutics
